Macquarie Group LTD Atreca, Inc. Transaction History

Macquarie Group LTD

  • $90.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022
SELL
$2.87 - $6.29 $18,270 - $40,042
-6,366 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$7.82 - $13.8 $43,784 - $77,266
5,599 Added 729.99%
6,366 $54,000
Q2 2020

Aug 11, 2020
BUY
$12.52 - $23.45 $9,602 - $17,986
767 New
767 $16,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email